191 related articles for article (PubMed ID: 35151865)
1. A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion.
Rybin MJ; Laverde-Paz MJ; Suter RK; Affer M; Ayad NG; Feng Y; Zeier Z
Bioorg Med Chem Lett; 2022 Apr; 61():128614. PubMed ID: 35151865
[TBL] [Abstract][Full Text] [Related]
2. Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights.
Al-Sanea MM; Elkamhawy A; Paik S; Lee K; El Kerdawy AM; Syed Nasir Abbas B; Joo Roh E; Eldehna WM; Elshemy HAH; Bakr RB; Ali Farahat I; Alzarea AI; Alzarea SI; Alharbi KS; Abdelgawad MA
Bioorg Med Chem; 2020 Jul; 28(13):115525. PubMed ID: 32371117
[TBL] [Abstract][Full Text] [Related]
3. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
[TBL] [Abstract][Full Text] [Related]
4. Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors.
Qi B; Xu X; Yang Y; He H; Yue X
Bioorg Med Chem; 2019 Sep; 27(17):3825-3835. PubMed ID: 31307762
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.
Bo YX; Xiang R; Xu Y; Hao SY; Wang XR; Chen SW
Bioorg Med Chem; 2020 Mar; 28(5):115351. PubMed ID: 32035750
[TBL] [Abstract][Full Text] [Related]
6. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Alafate W; Wang M; Zuo J; Wu W; Sun L; Liu C; Xie W; Wang J
Pathol Res Pract; 2019 Nov; 215(11):152617. PubMed ID: 31563286
[TBL] [Abstract][Full Text] [Related]
7. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel 1,3,4-thiadiazole derivatives as anti-glioblastoma agents targeting the AKT pathway.
Szeliga M; Karpińska M; Rola R; Niewiadomy A
Bioorg Chem; 2020 Dec; 105():104362. PubMed ID: 33074121
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinases as targets in drug-resistant neuroblastoma cells.
Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
[TBL] [Abstract][Full Text] [Related]
10. Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.
Zhang L; Yang Z; Sang H; Jiang Y; Zhou M; Huang C; Huang C; Wu X; Zhang T; Zhang X; Wan S; Zhang J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1541-1552. PubMed ID: 34238111
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Discovery and Bioactivity Evaluation of Novel Aurora-A Kinase Inhibitors as Anticancer Agents via Docking-Based Comparative Intermolecular Contacts Analysis (dbCICA).
Hijjawi MS; Abutayeh RF; Taha MO
Molecules; 2020 Dec; 25(24):. PubMed ID: 33353031
[TBL] [Abstract][Full Text] [Related]
12. Suppression of LIM Kinase 1 and LIM Kinase 2 Limits Glioblastoma Invasion.
Chen J; Ananthanarayanan B; Springer KS; Wolf KJ; Sheyman SM; Tran VD; Kumar S
Cancer Res; 2020 Jan; 80(1):69-78. PubMed ID: 31641031
[TBL] [Abstract][Full Text] [Related]
13. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
14. Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer.
Dokla EME; Abdel-Aziz AK; Milik SN; Mahmoud AH; Saadeldin MK; McPhillie MJ; Minucci S; Abouzid KAM
Bioorg Chem; 2021 Dec; 117():105451. PubMed ID: 34736137
[TBL] [Abstract][Full Text] [Related]
15. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
Kalous O; Conklin D; Desai AJ; Dering J; Goldstein J; Ginther C; Anderson L; Lu M; Kolarova T; Eckardt MA; Langerød A; Børresen-Dale AL; Slamon DJ; Finn RS
Breast Cancer Res Treat; 2013 Oct; 141(3):397-408. PubMed ID: 24091768
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.
Cai J; Li L; Hong KH; Wu X; Chen J; Wang P; Cao M; Zong X; Ji M
Bioorg Med Chem; 2014 Nov; 22(21):5813-23. PubMed ID: 25270403
[TBL] [Abstract][Full Text] [Related]
17. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
[TBL] [Abstract][Full Text] [Related]
18. Optimization and biological evaluation of 2-aminobenzothiazole derivatives as Aurora B kinase inhibitors.
Lee E; An Y; Kwon J; Kim KI; Jeon R
Bioorg Med Chem; 2017 Jul; 25(14):3614-3622. PubMed ID: 28529042
[TBL] [Abstract][Full Text] [Related]
19. Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
Chang Hsu Y; Ke YY; Shiao HY; Lee CC; Lin WH; Chen CH; Yen KJ; Hsu JT; Chang C; Hsieh HP
ChemMedChem; 2014 May; 9(5):953-61. PubMed ID: 24665000
[TBL] [Abstract][Full Text] [Related]
20. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]